Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Deruxtecan With Bevacizumab Versus Bevacizumab Monotherapy as First-line Maintenance Therapy in HER2-Expressing Ovarian Cancer
NCT06819007Phase 3Recruiting
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2025
- Primary completion
- Nov 2028
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 26
01
Overview
A Phase 3 trial of trastuzumab deruxtecan in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal carcinoma (PPC), sponsored by Daiichi Sankyo Co., Ltd.. Started Mar 2025; status: recruiting.
02
Drugs
trastuzumab deruxtecan
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal carcinoma (PPC)
Beyond the preview
Go deeper on NCT06819007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06819007.